AstraZeneca And Daiichi’s Dato-DXd Set For More Modest Market Entry Than First Hoped

After setbacks and a withdrawn filing, Dato-DXd is back on track for a potential second-line approval later this year in EGFR-mutant lung cancer. The partners are still counting on success in first line lung cancer and breast cancer treatment